Updated findings from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (NCT04221945) show the survival advantages of ...

“We know [immunotherapy] can work in untreated or previously treated but ... in a review of the topic at the recent World Conference on Lung Cancer. But how does a large molecule, like pembrolizumab, ...

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Third Quarter 2024 Results Conference Call. At ...

Should you invest in Bicara Therapeutics Inc? Click for more on BCAX's promising cancer treatment, but proceed with caution ...

Keytruda contains the active ingredient pembrolizumab. (An active ingredient is what makes a drug work.) Keytruda is a biologic medication. A biologic is made from parts of living organisms.

Revolution Medicines, Inc. (NASDAQ: RVMD) Q3 2024 Earnings Call Transcript November 6, 2024 Revolution Medicines, Inc. misses on earnings expectations. Reported EPS is $-0.94 EPS, expectations were ...

ALPMF's expanding lineup of cancer drugs, including zolbetuximab, positions them for substantial market growth and potential appreciation.

We do not intend to update publicly any forward ... LUNAR-2 is studying Tumor Treating Fields, together with platinum chemotherapy and pembrolizumab, in the first line. LUNAR-4 is setting ...

Q3 2024 Earnings Call Transcript October 30, 2024 NovoCure Limited beats earnings expectations. Reported EPS is $-0.28, expectations were $-0.34. Operator: Good day, and thank you for standing by.

It does not include potential payments resulting from the outcomes ... clinical trial evaluating BNT316/ONC-392 in combination with pembrolizumab in patients with platinum-resistant ovarian cancer ...

Survival for patients with glioblastoma brain tumour is 12–18 months from diagnosis. Some tumours may respond well to immunotherapy, but there is currently no way to assess response and adapt ...